Loading organizations...
§ Private Profile · 2330 Faraday Ave Ste 100, Carlsbad, California, 92008, United States
Genomics technology developer offering High-Definition PCR (HDPCR) multiplexing platforms for clinical genomics and molecular diagnostics.
Carlsbad, California-based ChromaCode develops a genomics multiplexing platform utilizing High-Definition PCR technology to enable rapid, accurate, and cost-effective molecular diagnostics testing. The company's proprietary software platform leverages existing real-time PCR instruments combined with advanced digital signal processing to improve clinical genomics analysis, focusing on actionable oncology biomarkers. To support its ongoing research and commercialization efforts, the enterprise has secured venture capital backing from prominent institutional investors such as NEA, Domain Associates, and Global Brain. This financial support notably includes a $12 million Series B funding round completed in 2017 to scale its laboratory solutions and expand operations. Furthermore, the firm has established strategic partnerships with international entities like MedGenome to expand its diagnostic solutions into markets across India and the Middle East. ChromaCode was founded in 2012 by Alex Dickinson, Aditya Rajagopal, and Greg Gosch.
ChromaCode has raised $50.0M across 3 funding rounds.
ChromaCode has raised $50.0M in total across 3 funding rounds.
ChromaCode has raised $50.0M across 3 funding rounds. Most recently, it raised $10.0M Series C in May 2020.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 1, 2020 | $10M Series C | Adjuvant Capital | G20 Ventures | Announced |
| Dec 1, 2019 | $28M Series C | PAT Smerkers | Domain Associates, Endeavor Venture Funds, MPM Capital, Vensana Capital, California Institute OF Technology, Moore Venture Partners, Carol Gallagher, Okapi Venture Capital, Windham Venture Partners | Announced |
| Apr 1, 2017 | $12M Series B | Justin Klein | Domain Associates, Endeavor Venture Funds, MPM Capital, Vensana Capital, Okapi Venture Capital | Announced |
ChromaCode has raised $50.0M in total across 3 funding rounds.
ChromaCode's investors include Adjuvant Capital, G20 Ventures, Pat Smerkers, Domain Associates, Endeavor Venture Funds, MPM Capital, Vensana Capital, California Institute of Technology, Moore Venture Partners, Carol Gallagher, Okapi Venture Capital, Windham Venture Partners.
ChromaCode is a biotechnology company specializing in HDPCR™ (High-Definition PCR) multiplexing technology for genomic solutions, enabling labs and physicians to detect multiple biomarkers rapidly and cost-effectively without new hardware.[1][2][3] It serves clinical labs, particularly in oncology and genomics, solving the problem of limited multiplexing in traditional digital PCR (dPCR) by delivering over 4x more biomarkers per well, under 24-hour turnaround, and high margins (≥80%) via reagent kits and ChromaCode Cloud software.[1][3] This platform bridges the gap between slow, complex next-generation sequencing (NGS) and basic PCR, providing NGS-quality multi-analyte results scalably on existing instruments.[1][3]
Growth momentum includes commercialization of HDPCR for oncology profiling, partnerships for custom assays, and proof-of-concepts in minimal residual disease (MRD) monitoring, backed by investors like Global Brain.[4][5] Spun out of Caltech, the company is pursuing pre-IPO opportunities while expanding into broader genomic applications.[5][6]
ChromaCode originated as a spinout from Caltech, founded around 2012 with its core HDPCR technology developed by founder Aditya, who serves as Chief Technology Officer (CTO).[5][6] CEO Mark McDonough joined later, highlighting the team's impressive innovation in a 2023 investor video, emphasizing the tech's incubation at Caltech and early focus on efficient molecular profiling.[5]
The idea emerged from advancing PCR multiplexing beyond conventional limits (typically 5 targets per well) using proprietary chemistry and cloud-based decoding, addressing needs for faster clinical decisions in genomics.[1][2][5] Early traction came via lab validations, such as at the University of Minnesota Medical School, and investment from Global Brain, positioning it for oncology and beyond.[1][4]
ChromaCode rides the precision oncology and genomics trend, where demand for rapid, multi-biomarker profiling aligns with NCCN guidelines amid rising cancer cases and value-based care shifts.[1][2][5] Timing is ideal as labs reject costly NGS for routine use, creating opportunities for HDPCR's speed and affordability in high-volume testing like tumor profiling and MRD.[5]
Market forces favoring it include falling sequencing costs but persistent NGS bottlenecks, plus AI-driven diagnostics growth (e.g., parallels with Viz.ai/Aidoc), enabling broader access to actionable biomarkers and reducing health inequities.[2][5] It influences the ecosystem by empowering labs to scale genomic assays, fostering partnerships, and accelerating personalized medicine without infrastructure overhauls.[1][3]
ChromaCode is poised to capture share in molecular diagnostics, expanding from oncology proofs-of-concept to MRD, transplant monitoring, and custom partner assays, potentially via regulatory approvals and larger funding rounds toward IPO.[5][6] Trends like AI-enhanced workflows, real-world data integration, and cost pressures in healthcare will amplify HDPCR's edge, evolving its role from lab enabler to platform leader in accessible genomics.[2][3][5]
This positions ChromaCode to transform patient outcomes, much like its Caltech roots promised—delivering multiplexing efficiency that equips labs to serve more patients globally.[1][5]